Overview
Introduction
The need to overcome the pharma industrys pipeline productivity crisis is
forcing the genomics innovators and their partners to reshape their portfolio
management. New asset allocation strategies and valuation methodologies are
needed to support the evolution to a new business model emphasizing investment
in technological diversification.
Scope
- Reveals the dynamics of the genomics diversification in accordance with
the evolution of the new bio/pharma supply chain
- Proposes survival strategies for potential postgenomics drug developers
and successful exit strategies for failed genomics businesses
- Introduces novel portfolio management and option based asset valuation to
support postgenomics drug developers, genomics licensees and innovators
Report Highlights
The early wave of the genomics revolution witnessed a spectacular stock value
decline. This was caused by the lack of transparency between the industrys
innovating, investing and licensing arms, and by a high degree of speculation
related to unrealistic market generation targets and lack of understanding of
the technological complexities.
The new wave of innovation is focusing on gene functionalities, population
genomics, chemo- and pharmacogenomics. Drug developers should continue
integrating well-defined genomics assets into their supply chains, work to
maximize successful target validation and optimize alliance networks to ensure
asset co-evolution and diversification.
Conventional discount flow-based asset valuation cannot describe the
complexity of each genomics asset. Therefore, blending quantitative real option
based and qualitative multifactorial asset analysis models can offer flexible
long-term asset allocation and a number of capital growth opportunities hidden
in genomics assets.
Reasons to Purchase
- Understand the dynamics behind the early genomics devaluation, and develop
winning business survival and successful postgenomics exit strategies
- Gain insight into how the new wave of genomics diversification helps the
bio/pharma supply chain to recover from its current productivity crisis
- Improve genomics project valuation by combining novel multidimensional
asset analysis for less supply chain complexity, with real option based
methods
View Cart
